Triplet immunotherapy-based regimen shows promise for relapsed, refractory DLBCL

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 13 / Springer Healthcare

Triplet immunotherapy-based regimen shows promise for relapsed, refractory DLBCL

CHRU Hôpital Huriez, Lille, France

Haematology EHA-2020

Description

Charles Herbaux presents the primary analysis of the phase 2 GATA study showing the potential of combining atezolizumab, obinutuzumab and venetoclax for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.